Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia Clinical Trial

Official title:

Consolidation Therapy With Alemtuzumab (MabCampath®) in Patients With Chronic Lymphocytic Leukemia Who Are in Complete or Partial 2nd Remission After Cytoreduction With Fludarabine or Fludarabine Plus Cyclophosphamide or Fludarabine Plus Cyclophosphamide Plus Rituximab or Bendamustine or Bendamustine Plus Rituximab - a Phase I/II Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00634881
• Other study ID #: CLL2i
• Secondary ID: CDR0000587746
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 2003
• Est. completion date: February 17, 2012

Study information

• Verified date: June 2019
• Source: German CLL Study Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.

PURPOSE: This phase I/II trial is studying the side effects and best dose of alemtuzumab in treating patients with B-cell chronic lymphocytic leukemia.

Description:

OBJECTIVES:

• To determine the safest dose of alemtuzumab as consolidation therapy in patients in second remission after fludarabine phosphate alone; fludarabine phosphate and cyclophosphamide; fludarabine phosphate, cyclophosphamide, and rituximab; bendamustine hydrochloride alone; or bendamustine hydrochloride and rituximab.

• To determine the frequency of cytomegalovirus reactivations or infections during or after alemtuzumab treatment.

• To determine which dose of alemtuzumab is efficient to eliminate minimal residual disease in peripheral blood and bone marrow (i.e., to turn a clinical partial remission into a clinical complete remission [CR], to turn a flow cytometry-positive CR into a flow cytometry-negative CR, or to turn a PCR-positive CR into a PCR-negative CR).

• To determine the pharmacokinetic profile of alemtuzumab.

• To compare the pharmacokinetic profile between intravenous versus subcutaneous administration of alemtuzumab.

OUTLINE: This is a multicenter, dose-escalation study of alemtuzumab.

• Group 1: Patients receive escalating doses of alemtuzumab IV over 2 hours once weekly for 8 weeks until the maximum tolerated dose (MTD) is determined.

• Group 2: Patients receive escalating doses of alemtuzumab subcutaneously once weekly for 8 weeks, beginning with the MTD determined in group 1 until a second MTD is determined.

Patients undergo bone marrow and blood sample collection periodically for laboratory and pharmacokinetic studies. Samples are analyzed for minimal residual disease and T-cell subsets (i.e., CD4 and CD8) via quantitative-PCR analysis and flow cytometry and cytomegalovirus antigens via PCR.

After completion of study treatment, patients are followed at 3, 6, 9, 12, 18, and 24 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: February 17, 2012
• Est. primary completion date: January 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

Inclusion criteria:

• Diagnosis of B-cell chronic lymphocytic leukemia (B-CLL)

• Disease in complete or partial remission after completion of 4-6 courses of second-line cytoreductive therapy no less than 90 days and no more than 150 days ago

• Second-line cytoreductive therapy must comprise 1 of the following regimens:

• Fludarabine phosphate alone (F)

• Fludarabine phosphate and cyclophosphamide (FC)

• Fludarabine phosphate, cyclophosphamide, and rituximab (FCR)

• Bendamustine hydrochloride alone (B)

• Bendamustine hydrochloride and rituximab chemotherapy (BR)

• Complete minimal residual disease response defined by the following:

• At least negativity of 4-color-cytometry and/or even PCR-amplifiable clonal CDR III rearrangement of the IgV_H

• For PCR analysis, blood sample need to be taken at beginning or during second-line cytoreductive therapy before achievement of a clinical complete remission

• Disease not refractory to first-line F/FC/FCR/B/BR if received such therapy

Exclusion criteria:

• Presence of bulky lymph nodes (> 5 cm) after second-line F/FC/FCR/B/BR

• Clinically apparent autoimmune cytopenia (i.e., autoimmune hemolytic anemia, autoimmune thrombocytopenia, or pure red cell aplasia)

• CNS involvement with B-CLL

PATIENT CHARACTERISTICS:

Inclusion criteria:

• ECOG performance status 0-1

• ANC = 1,500/µL

• Platelets = 50,000/µL

• Creatinine = 1.5 times the upper normal limit (ULN)

• Conjugated bilirubin = 2 times ULN

• Thyroid function normal

• Not pregnant or nursing

• Fertile patients must use effective contraception

Exclusion criteria:

• Severe infection during second-line treatment with F/FC/FCR/B/BR, meeting any 1 of the following criteria:

• Any episode of NCI grade 4 infection

• More than 1 episode of NCI grade 3 infection

• Medical condition requiring long-term use of oral corticosteroids for more than 1 month

• Active bacterial, viral, or fungal infection

• HIV, hepatitis B virus, and/or hepatitis C virus-positive serum status

• Concurrent severe diseases that exclude the administration of protocol therapy, including any of the following:

• NYHA class III-IV heart insufficiency

• Severe chronic obstructive lung disease with hypoxemia

• Severe ischemic cardiac disease

• Active secondary malignancy other than B-CLL prior to the study

• Known hypersensitivity or anaphylactic reaction against murine proteins or one of the drug components

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No more than 2 prior chemotherapies, including F/FC/FCR/B/BR therapy

• No more than 1 pretreatment (before second-line therapy) with chlorambucil or F/FC/FCR/B/BR

• No chemotherapy or radiotherapy for any neoplastic disease other than B-CLL prior to the study

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Intervention

Biological:
• Alemtuzumab i.v.
Alemtuzumab will be administered once per week as a 2 h infusion Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3) Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)
• Alemtuzumab s.c.
Alemtuzumab will be administered once per week subcutaneously Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3) Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)

Locations

Country	Name	City	State
Germany	Medizinische Universitaetsklinik I at the University of Cologne	Cologne
Germany	Klinikum Barnim GmbH, Werner Forssmann Krankenhaus	Eberswalde
Germany	Universitatsklinikum Heidelberg	Heidelberg
Germany	Klinikum Lippe - Lemgo	Lemgo
Germany	III Medizinische Klinik Mannheim	Mannheim
Germany	Krankenhaus Barmherzige Brueder Regensburg	Regensburg

Sponsors (1)

Lead Sponsor	Collaborator
German CLL Study Group

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J, Elter T, Stilgenbauer S, Eichhorst BF, Busch R, Elberskirch U, Abenhardt W, Kneba M, Hallek M, Wendtner CM. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicen — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting toxicity	• Dose-limiting toxicity (DLT) and maximal tolerable dose (MTD) DLT is defined as a) all grade III/IV non-hematologic toxicity and b) all grade IV hematologic toxicity lasting for more than 2 weeks (excluding lymphopenia) occuring during or within 4 weeks after end of consolidation therapy.	28 days after the last dose of study medication
Primary	Maximum tolerated dose	• Dose-limiting toxicity (DLT) and maximal tolerable dose (MTD) DLT is defined as a) all grade III/IV non-hematologic toxicity and b) all grade IV hematologic toxicity lasting for more than 2 weeks (excluding lymphopenia) occuring during or within 4 weeks after end of consolidation therapy.	28 days after the last dose of study medication
Secondary	Rate of complete minimal residual disease response	• Rate of molecular responses (defined by negativity of 4- colour- cytometry in BOTH peripheral blood AND bone marrow in patients in clinical CR) The approved laboratory diagnostics for detection of MRD response is 4-colour flow cytometry. Collaterally, it is possible to take samples for potential PCR- analysis for confirmation if available.	will be tested repeatedly, first time 3 months after the last dose of study medication, last time point 24 months after last dose of study medication
Secondary	Rate of immunophenotypic remission using 4-color flow cytometry		will be tested repeatedly, first time 3 months after the last dose of study medication,
Secondary	Rate of infections (especially CMV infections and reactivations)		upt to 24 months after last dose of study medication (end of study)
Secondary	Rate of severe hematologic and non-hematologic side effects		28 days after the last dose of study medication
Secondary	Pharmacokinetics of alemtuzumab (after IV and subcutaneous administration)	Pharmacokinetic samples will be taken at week 4 and 8 during alemtuzumab treatment at the following time points: 0, 4, 8, 24, 48, 96, 168 h	up to 8 weeks during the alemtuzumab treatment
Secondary	Progression-free survival		upt to 24 months after last dose of study medication (end of study)
Secondary	Overall survival		upt to 24 months after last dose of study medication (end of study)
Secondary	Complete remission rate		28 days after the last dose of study medication

External Links

•   Click here for more information about this study: CLL2i (German CLL Study Group)